Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: Mycophenolate mofetil and enteric-coated mycophenolate sodium

Transplantation

Volumn 92, Issue 4, 2011, Pages 426-432

  Ortega, Francisco ^a   Sánchez Fructuoso, Ana ^b   Cruzado, José María ^c   Gómez Alamillo, Juan Carlos ^d   Alarcón, Antonio ^e   Pallardó, Lluís ^f   Morales, José María ^g   Oliver, Juan ^h   Guinea, Guillermo ⁱ  

^a H U Central de Asturias   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c Service of Nephrology   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL SON DURETA   (Spain)

^f H Dr Peset   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h UNIVERSITY OF A CORUÑA   (Spain)

ⁱ Medical Department   (Spain)

Author keywords

Gastrointestinal disorders; Immunosuppression; Kidney transplantation; Mycophenolate mofetil; Mycophenolate sodium

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTON PUMP INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INDIGESTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; VOMITING;

ADULT; DIARRHEA; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; QUALITY OF LIFE; TABLETS, ENTERIC-COATED;

EID: 80051785897     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822527ca     Document Type: Article

References (29)

1. Veroux M, Corona D, Veroux P. Kidney transplantation: Future challenges. Minerva Chir 2009;64:75.
2. Marcen R. Immunosuppressive drugs in kidney transplantation: Impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69:2227.
3. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005;80(suppl 2):S221.
4. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007;7:560.
5. Golshayan D, Pascual M, Vogt B. Mycophenolic acid formulations in adult renal transplantation-Update on efficacy and tolerability. Ther Clin Risk Manag 2009;5:341.
6. Sabbatini M, Capone D, Gallo R, et al. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009;23:617.
7. Sanford M, Keating GM. Enteric-coated mycophenolate sodium: A review of its use in the prevention of renal transplant rejection. Drugs 2008;68:2505.
8. Darji P, Vijayaraghavan R, Thiagarajan CM, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008;40:2262.
9. Salvadori M, Budde K, Holzer H, et al. EC-MPS is associated with superior efficacy outcomes compared to MMF in de novo kidney transplant patients: A pooled analysis. In: ASN Renal Week, San Diego, CA, 2009.
10. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4:231.
11. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004;4:237.
12. Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007;84:1443.
13. Shehata M, Bhandari S, Venkat-Raman G, et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int 2009;22:821.
14. Gozdowska J, Urbanowicz A, Baczkowska T, et al. Safety and tolerance of sodium mycophenolate in patients after renal transplantation-An observational study. Transplant Proc 2009;41:3016.
15. Hardinger KL, Hebbar S, Bloomer T, et al. Adverse drug reaction driven immunosuppressive drug manipulations: A single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant 2008;22:555.
16. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006;81:1290.
17. Cofan F, Rosich E, Arias M, et al. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 2007;39:2179.
18. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381.
19. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns onclinical outcome after renal transplantation. Clin Transplant 2003;17:200.
20. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005;19:779.
21. Shah S, Collett D, Johnson R, et al. The effectof mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United Kingdom. Transplantation 2008;86:1035.
22. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007;7:888.
23. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496.
24. Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001;47:88.
25. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136.
26. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. Br J Surg 1995;82:216.
27. Dimenas E, Glise H, Hallerbäck B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046.
28. Dimenas E, Carlsson G, Glise H, et al. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996;221:8.
29. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: L. J. Publishing, ed. Assessment of quality of life in clinical trials of cardiovascular therapies. Washington, Le Jacq Publishing 1984, pp 170.